Proinflammatory cytokines have been shown to influence the expression and function of the glucocorticoid receptor (GR). Specifically, several studies have found that cytokines induce a decrease in GR function, as evidenced by reduced sensitivity to glucocorticoid effects on functional end points. To investigate the potential mechanism(s) involved, we examined the impact of the proinflammatory cytokine, interleukin-1␣ (IL-1␣), on 1) GR translocation from cytoplasm to nucleus using GR immunostaining, 2) cytosolic radioligand GR binding, and 3) GR-mediated gene transcription in L929 cells stably transfected with the mouse mammary tumor virus-cholamphenicol acetyltransferase reporter gene. L929 cells were treated with IL-1␣ (100 and 1000 U/ml) for 24 h in the presence or absence of dexamethasone (Dex; 10 nM to 1 M). IL-1␣ inhibited Dex-induced GR translocation and alone induced GR up-regulation. Pretreatment with IL-1␣ followed by Dex treatment for 1.5 h led to about 20% inhibition of Dex-induced GR-mediated gene transcription, whereas coincubation of IL-1␣ plus Dex for 24 h inhibited Dex-induced GR-mediated gene activity up to 42%. The latter effect was reversed by the IL-1 receptor antagonist. These results suggest that cytokines produced during an inflammatory response may induce GR resistance in relevant cell types by direct effects on the GR, thereby providing an additional pathway by which the immune system can influence the hypothalamic-pituitaryadrenal axis. (Endocrinology 140: 4359 -4366, 1999) 
G LUCOCORTICOIDS have potent effects on virtually
every aspect of the immune response. Glucocorticoids inhibit the production and release of a host of cytokines and inflammatory mediators and regulate immune cell distribution throughout the body (1, 2) . Pharmacological doses of glucocorticoids (including their synthetic analogs) are well known for their efficacy in the treatment of autoimmune and inflammatory disorders (3) . Glucocorticoids from endogenous sources also appear to be relevant to immune regulation and disease expression. For example, glucocorticoid blockade exacerbates or precipitates the expression of autoimmune disorders in laboratory animals, and in the case of viral infection, removal of adrenal sources of glucocorticoid hormones potentiates the lethal effects of virus-induced inflammatory responses (4, 5) . In further support of a relevant role of glucocorticoids in immune regulation, numerous studies have characterized the capacity of the immune system via proinflammatory cytokines, including interleukin-1 (IL-1), IL-6, and tumor necrosis factor, to activate the hypothalamicpituitary-adrenal (HPA) axis with the resultant release of glucocorticoids (5) . Activation of endogenous glucocorticoids by proinflammatory cytokines is believed, in turn, to modulate evolving immune responses, comprising a regulatory feedback loop between the HPA axis and the immune system (2, 5) .
Glucocorticoids mediate their effects on target immune tissues via two distinct receptor subtypes, the mineralocorticoid receptor and the glucocorticoid receptor (GR). Although the mineralocorticoid receptor has a higher affinity for circulating glucocorticoids than the GR, the GR is expressed in much higher amounts in immune tissues (6) . In addition, there is a great degree of heterogeneity in GR expression among immune cells and tissues, allowing for cell-and tissue-specific responses to glucocorticoids (6 -8) . Interestingly, studies have shown that aside from activating glucocorticoid release, cytokines can also influence the expression and function of GR. For example, in vivo and in vitro treatment with cytokines and cytokine inducers (e.g. endotoxin) has been found to alter GR expression and function in a number of cells and tissues, including T cells (9) , monocytes/macrophages (10, 11) , bronchial cells and lung (12, 13) , and liver (11, 14 -18) . A number of these studies have demonstrated that treatment with cytokines induces a decrease in GR function (GR resistance), as evidenced by decreased sensitivity to the effects of glucocorticoids on functional end points (9, 15, 17, 18) and decreased GR affinity for ligand (9 -12) . Studies performed on peripheral cells and tissues of patients with inflammatory diseases such as asthma, ulcerative colitis, acquired immunodeficiency syndrome, and rheumatoid arthritis, especially those showing resistance to the therapeutic effects of glucocorticoids, also have demonstrated reductions in GR function and affinity that are similar to those induced by in vivo and in vitro treatment with cytokines (19 -25) . Thus, converging evidence suggests that cytokines produced during an inflammatory response may directly modulate the capacity of glucocorticoids to transmit signals to target tissues and induce GR resistance in relevant cell types. Moreover, given the role of GR in mediating feedback inhibition on the HPA axis, the effects of cytokine on GR function may provide an additional pathway by which the immune system can influence HPA axis activity.
To investigate potential mechanism(s) by which cytokines might inhibit GR function, we examined whether the proinflammatory cytokine, IL-1␣, disrupts translocation of the GR from the cytoplasm to the nucleus. According to the nucleocytoplasmic traffic model, the GR in its unactivated form resides primarily in the cytoplasm, and after being bound by steroid undergoes a conformational change (activation), dissociates from a multimeric complex including several heat shock proteins, and translocates from the cytoplasm to the nucleus, where it either binds to hormone response elements (HREs) on DNA or interacts with other transcription factors (26, 27) . Experiments were conducted in a mouse fibroblast cell line (L929 cells), as fibroblasts are an important stromal cell type involved in the acute phase response and have been shown to express receptors for IL-1 at a high density (ϳ5000 sites/cell) (28) . IL-1␣ was chosen based on our previous studies in experimental murine viral infections, where we have found that IL-1␣ (along with IL-6) plays a pivotal role in the induction of glucocorticoids during viral infection (29) . Cells were treated with IL-1␣ for 24 h in the presence or absence of the synthetic steroid, dexamethasone (Dex), and GR translocation was investigated using GR immunostaining of the receptor in the cytoplasm and nucleus. In addition, evaluation of GR number was performed using cytosolic radioligand receptor binding. Finally, GR function was measured by means of GR-mediated gene transcription in L929 cells stably transfected with the mouse mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter gene.
Materials and Methods Materials
Unlabeled Dex was obtained from Sigma Chemical Co. (St. Louis, MO). [6,7-N-3 H]Dex (43.2 Ci/mmol) was obtained from New England Nuclear (Boston, MA). Human fibronectin was obtained from Becton Dickinson and Co. (Franklin Lakes, NJ). Recombinant murine IL-1␣ was purchased from R&D Systems (Minneapolis, MN). The LMCAT cell line was provided by E. R. Sanchez (Department of Pharmacology, Medical College of Ohio, Toledo, OH). IL-1 receptor antagonist (IL-1ra) was a gift from Synergen (Boulder, CO).
Cell culture conditions and drug treatments
Mouse fibroblast cells (L929) and the stably transfected CAT reporter cell line LMCAT (derived from L929, see Ref. 30) were maintained in 175-cm 2 flasks (Becton Dickinson and Co.) at 37 C with a 5% CO 2 and 95% air atmosphere. L929 cells were maintained in DMEM with 50 U/ml penicillin, 50 g/ml streptomycin, and 10% heat-inactivated (56 C, 30 min) calf serum. LMCAT cells were maintained in DMEM with 0.2 mg/ml G418 (geneticin) antibiotic and 10% heat-inactivated (56 C, 30 min) newborn calf serum that had been charcoal extracted (1% activated charcoal-0.1% dextran) to remove endogenous steroids. For immunostaining, cells were subcultured in fibronectin-coated chamber slides (Nunc, Naperville, IL) in DMEM with 50 U/ml penicillin, 50 g/ml streptomycin, and 10% charcoal-extracted bovine calf serum for 12 h to obtain a final confluence of approximately 70% and then treated. For binding assays, L929 cells were subcultured in fibronectin-coated 175-cm 2 flasks in DMEM with 50 U/ml penicillin, 50 g/ml streptomycin, and 10% heat-inactivated calf serum for 48 -72 h (final confluence, 95%) before treatment. For the CAT assay, LMCAT cells were subcultured in their usual growth medium in fibronectin-coated six-well plates and grown for 12 h (final confluence, 95%) before treatment. Treatment of both L929 cells and LMCAT for all assays consisted of incubation with fresh medium containing final concentrations of IL-1␣ (100 and 1000 U/ml) and Dex (10 nm to 1 M). This range of concentrations has been used in previous studies examining the impact of cytokines on the GR.
Immunostaining procedures and fluorescence quantitation
Immunostaining for the GR was performed as described previously (31) . Cells were fixed/permeabilized with methanol at Ϫ20 C for 10 min, followed by 30-min incubation with 5% BSA to block nonspecific antibody binding. Cells were then incubated with the rabbit polyclonal antibody, clone 57 (GR57), against the human GR (catalog no. PA1-511, Affinity BioReagents, Inc., Golden, CO) (32) in 2% normal donkey serum (NDS) in PBS for 30 min at room temperature, followed by overnight incubation at 4 C. The following day, cells were incubated with biotinconjugated donkey antirabbit antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) in NDS for 1 h, followed by incubation with the fluorescein isothiocyanate-conjugated streptavidin (Jackson ImmunoResearch Laboratories, Inc.) in PBS for 1 h (in darkness). Two washes with PBS buffer were performed between all steps. Slides were mounted with a glass coverslip using the Slowfade-Light Antifade reagent in glycerol buffer (Molecular Probes, Inc., Eugene, OR). Microscopic examination was performed using a Nikon Microphot-SA microscope with a Nikon PlanApo 20/0.75 objective (Nikon, Melville, NY). The protocol for the quantitative analysis of fluorescence in the cytoplasm and the nucleus was developed in consultation with Dr. David E. Wolf (Cell Biology Group, Worcester Foundation for Biomedical Research, Worcester, MA) and has been previously validated and described (31) . A digital processing system including a computer station, NIH Image analysis software, and two devices for image acquisition (a camera and a scanner) was used to acquire, store, and process the microscopic images as well as to perform the quantitative analyses. Microscopic fields were captured under both light and fluorescence illuminations and transformed into digital images to be shown on a computer screen. Sampling was performed on two to four different areas of each well. The microscope and the camera settings were maintained constant between all experimental conditions, and no adjustment of the gray scale was performed in the images. A region of interest (ROI) was selected in the cytoplasm and nucleus of each cell of the section. The intensity value of each pixel within the ROI ranged between 0 -255 and was proportional to the number of fluorescent photons emitted from the corresponding point in the specimen. After subtraction of the background (no cells), the mean intensity of the ROI was calculated. This value represented a measure of the fluorescence detected from each ROI and was used to make comparisons between the same compartments under different conditions. Several steps were included to have an objective and accurate series of measurements. First, the ROI was initially outlined blind to the fluorescent signal (and to the treatment condition) using light microscopy images. Afterward the selections were superimposed onto the corresponding fluorescent image, and the fluorescence intensity in the region was quantified. Second, the ROI was defined using the oval tool of the image software, and its width was kept constant. Third, the entire cell and the nucleus were manually demarcated, and the resulting areas (number of pixels) were calculated to control for possible changes in the shape of the cells.
GR binding assay
GR binding was determined using a previously described in vitro cytosolic exchange assay (33) . After incubation with cytokine in 175-cm 2 flasks, cells were washed and scraped in cold HBSS, transferred to 50-ml tubes, pelleted at 700 ϫ g for 10 min, resuspended in HBSS for three consecutive washes, and then fractionated using a freeze/thaw procedure in a volume of 0.7 ml binding buffer (10 mm Tris, 1 mm EDTA, 20 mm molybdic acid, 5 mm dithiothreitol, and 10% glycerol in double distilled water, pH 7.4 at 4 C), yielding an approximate final protein concentration of 0.5-1.5 mg/ml cytosol. After centrifugation at 105,000 ϫ g for 60 min at 4 C, the supernatant-cytosol was added to incubation solutions containing radiolabeled ( 3 H) Dex with or without unlabeled competitor. Bound radiolabeled steroid was separated from unbound steroid by filtration through minicolumns containing 1.25 ml LH-20 
CAT reporter cell line and CAT assay
The LMCAT cell line (derived from L929 cells) is stably transfected with the MMTV-CAT reporter plasmid. Expression of CAT activity by these cells is under hormonal control by virtue of several HREs residing within the MMTV promoter, which lies upstream of the CAT reporter gene (30) . Measurement of CAT enzyme activity was performed using a liquid scintillation counting detection system according to the manufacturer's instructions (Promega Corp., Madison, WI). Briefly, cell extracts were obtained using a Tris buffer (0.25 m Tris-HCl, pH 8.0), freeze/thaw procedure, followed by heating to 60 C for 10 min to inactivate endogenous deacetylase activity. After centrifugation (20,000 ϫ g for 2 min), supernatants were transferred to fresh tubes and processed for CAT enzyme activity. Each reaction was initiated by adding the cofactor n-butyrl coenzyme A to tubes containing cell extracts and radiolabeled [ 3 H]chloramphenicol. The CAT reaction was stopped, and the butyrylated forms of [ 3 H]chloramphenicol were separated by three consecutive extractions with mixed xylene. The extracts were transferred to vials for liquid scintillation counting. The counts per min measured in each sample represents the butyrylated fraction of the enzyme (as determined by a standard curve) and is directly proportion to the CAT gene expression.
Protein content for all samples was determined by the method of Bradford (34) with use of BSA as a standard.
Statistical analysis
Data are presented as the mean Ϯ sem (sem) and were analyzed using one-way ANOVA. When ANOVA revealed a significant main effect of treatment condition, both a conservative (Student-Newman-Keuls test) and a powerful (Student's t test) post-hoc test were used for betweengroup comparisons.
Results

Effect of IL-1␣ on GR immunostaining
To examine the effect of IL-1␣ on GR nucleocytoplasmic traffic, we employed a fluorescence/immunostaining procedure using an anti-GR polyclonal antibody coupled with quantitative analysis of fluorescence in the cytoplasm and nucleus of cells using digital image analysis (see Materials and Methods). Cells were grown in steroid-free conditions (charcoal-extracted serum) and treated with vehicle, IL-1␣ (1000 U/ml) for 24 h, Dex (10 nm) for 1.5 h, or IL-1␣ (1000 U/ml) for 24 h followed by coincubation of IL-1␣ (1000 U/ml) plus Dex (10 nm) for 1.5 h. L929 cells stained for the GR after the various treatments are presented in Fig. 1 . After treatment with vehicle (Fig. 1A) , the pattern of staining was heterogeneous among cells, with a diffuse staining in both the cytoplasm and nucleus. In the majority of cells, the fluorescent signal was more intense in the cytoplasm than in the nucleus, although a few cells with brighter nuclei were present. Nucleoli were never stained. After treatment with Dex (10 nm; Fig. 1B) , cells presented more intense nuclear staining, confirming that treatment with Dex induced translocation of the GR from the cytoplasm to the nucleus [these results are consistent with our previous observation of GR immunostaining in L929 cells (31) ]. Cells treated with IL-1␣ alone for 24 h showed more intense and diffuse brightness in both cytoplasm and nucleus, but there was no apparent effect on GR translocation (Fig. 1C) . Finally, treatment with IL-1␣ and Dex (10 nm; Fig. 1D ) showed a reduced effect (less bright nuclei) compared with Dex alone.
We evaluated the fluorescence intensity in the cytoplasm and nucleus of approximately 460 cells, expressed as percentage of the fluorescence intensity of vehicle-treated cells (Fig. 2) . Quantitative analysis showed that Dex (10 nm) alone induced a decrease in the GR fluorescent signal in the cytoplasm of approximately 18%, whereas coincubation of IL-1␣ plus the same dose of Dex completely blocked the decrease in the cytoplasmic fluorescence. In the nucleus, Dex alone induced an increase in the signal of approximately 47%, whereas coincubation of IL-1␣ plus Dex led to a partial blocking of this effect, leading only to a 16% increase in nuclear fluorescence. Treatment with IL-1␣ alone induced an increase in both cytoplasmic (ϩ23%) and nuclear (ϩ16%) fluorescence, thus confirming the visual results of increased diffuse brightness.
To control for the specificity of the immunostaining for GR, a series of experiments was conducted in which the primary antibody anti-GR (GR57) was either preabsorbed against the immunogenic peptide (PEP-001, Affinity BioReagents, Inc., Boulder, CO) or substituted with NDS, or the second antibody (antirabbit IgG) was substituted with NDS. Controls were always negative. Fixed, but unstained, cells showed only minimal autofluorescence. There were no detectable differences among the various treatment conditions in the morphology of the cells or in the area of the entire cell or nucleus.
Effect of IL-1␣ on cytosolic GR binding
We evaluated [
3 H]Dex-binding sites using an in vitro exchange assay of cytoplasmic homogenates. When most of the receptor is in the unactivated state, cytosolic GR binding is a measure of the amount of receptor in the cells, and therefore, its evaluation may be useful to investigate expression of GR protein. L929 cells were treated with vehicle or IL-1␣ (1000 U/ml) for 24 h. As shown in Fig. 3A , IL-1␣ induced an increase in cytosolic GR binding (up-regulation). The increase in cytosolic binding (ϩ23%) is consistent with the increase in the cytoplasmic fluorescent signal (ϩ23%), thus suggesting that both of these techniques reveal increased levels of GR protein induced by treatment with IL-1␣ for 24 h. Protein concentrations were examined in every sample, and no effect of IL-1␣ treatment on protein content was detected [vehicle, 0.676 (se, 0.157) mg/ml; IL-1␣, 0.607 (se, 0.122) mg/ml; P ϭ NS].
Effects of IL-1 on GR-mediated gene transcription
To determine the functional correlates of IL-1␣-induced changes in nucleocytoplasmic traffic and protein expression, we examined GR-mediated gene transcription in L929 cells stably transfected with a CAT enzyme reporter gene that is under hormonal control by virtue of several HREs residing in the upstream MMTV promoter (LMCAT cells). According to our data on GR nucleocytoplasmic traffic and GR binding, IL-1␣ alone induced GR up-regulation in the absence of steroids, and cells treated with IL-1␣ and Dex showed less GR translocation than cells treated with the same dose of Dex alone. Therefore, to determine whether receptor up-regulation was accompanied by increased functional activity and whether blockade of Dex-induced GR translocation was associated with a relative decrease in functional activity, the impact of the same treatment protocols on GR-mediated gene transcription in the presence or absence of various doses of Dex was determined. LMCAT cells were grown in steroidfree medium and treated with vehicle, IL-1␣ (100 and 1000 U/ml) for 24 h, Dex (10 nm to 1 m) for 1.5 h, or IL-1␣ (10 -1000 U/ml) for 24 h followed by incubation of IL-1␣ (10 and 1000 U/ml) plus Dex (10 nm to 1 m) for 1.5 h. Results are presented in Figs. 3B and 4 and are expressed as relative CAT activity (percentage of vehicle-treated control samples). Treatment with IL-1␣ (1000 U/ml) alone for 24 h induced an increase in GR-mediated gene transcription (ϩ24%). This increase (ϩ24%) was consistent with the ϩ23% up-regulation induced by the same dose of IL-1␣ described previously in the immunostaining and binding data (Figs. 1, 2, and 3A) . In contrast, at every concentration of Dex, pretreatment with IL-1␣ (1000 U/ml) caused a decrease in Dex-induced GRmediated gene transcription compared with that in cells treated with the same dose of Dex alone (Fig. 4) . Dex-induced GR-mediated gene transcription was reduced by 4% at the 10-nm dose of Dex and about 20% at the 100-nm and 1-m Dex doses (Fig. 4) . As under physiological conditions, hormone and cytokine would occur together rather than in tandem as represented in the previous experiment, cells were coincubated with IL-1␣ and Dex for 24 h and compared with cells treated with Dex alone for 24 h. Previous experiments have demonstrated that under these conditions (Dex treatment for 24 h), GR down-regulation does not occur and therefore would not confound interpretation of the results (35) . Coincubation of cells with Dex plus IL-1␣ (100 and 1000 U/ml) led to marked reduction (42%) in relative CAT activity compared with treatment with Dex alone (Fig. 5A) . In addition, to confirm the specificity of the effects of IL-1␣ on GR-mediated gene transcription, IL-1ra was added to the combination of IL-1␣ plus Dex (10 nm). To optimize the stochiometry of the antagonist treatments in these experiments, the lower dose of IL-1␣ (100 U/ml) was used in combination with a 1000-fold excess of IL-1ra calculated on a mg per mg basis. As shown in Fig. 5B , IL-1ra completely eliminated the inhibitory effects of IL-1␣ on Dex-induced GR-mediated gene transcription.
Discussion
IL-1␣ inhibits GR translocation and function and induces GR up-regulation
The present study was conducted to investigate the effects of the proinflammatory cytokine, IL-1␣, on GR translocation and function. We used an in vitro experimental system employing the mouse fibroblast cell line L929, a cell line that has been previously described by our group and others to be sensitive to the effects of GR agonists, antagonists, and nonsteroid GR modulators, including antidepressants (31), heat shock (30) , and cytokines (36) . We also used a panel of quantitative assays to investigate GR nucleocytoplasmic traffic, GR expression, and GR-mediated gene transcription. Our results demonstrate that 24-h treatment with IL-1␣ inhibits Dex-induced translocation of the GR from cytoplasm to nucleus. Moreover, 24-h pretreatment with IL-1␣ or 24-h coincubation with IL-1␣ led to significant reduction in Dexinduced GR-mediated gene transcription, an effect that was reversed by IL-1ra. Finally, evaluation of both immunocytochemical staining of the GR and cytosolic GR binding in cells treated with IL-1␣ for 24 h provided evidence of GR up-regulation.
These results contribute to the identification of a possible mechanism by which cytokines can induce glucocorticoid resistance. As previously noted, several studies have shown that in vivo and in vitro treatment with proinflammatory cytokines, including IL-1, decreases GR function (GR resistance). For example, in vivo treatment of mice or in vitro treatment of a hepatoma cell line with IL-1␣ and IL-1␤ has been found to decrease glucocorticoid-stimulated induction of the gluconeogenesis enzyme, phosphenolpyruvate carboxykinase (15, 17, 18) . Of note is that the degree of maximum inhibition of enzyme induction in these previous studies (ϳ25%) is comparable to the percent inhibition of GR-mediated gene transcription found in the present study (20 - LMCAT cells were grown in steroid-free medium and treated with vehicle (Ⅺ), Dex (10 nM) for 24 h (f), Dex (10 nM) plus IL-1␣ (100 -1000 U/ml) for 24 h ( , ), or Dex (10 nM), IL-1␣ (100 U/ml), and IL-1ra for 24 h ( ); in panel B only). Cells were fractionated, and lysates were analyzed for relative CAT enzyme activity (presented as a percentage of vehicle activity). A, Results depicted are from a representative experiment in which the mean Ϯ SEM of five or six separate determinations per treatment group are shown. There was a significant main effect of treatment condition on GR-mediated gene activity using one-way ANOVA [F(2,16) ϭ 10.41; P Ͻ 0.002]. These results were replicated in two (1000 U/ml) to six (100 U/ml) independent experiments. *, Significant (P Ͻ 0.05) difference from the indicated group vs. the vehicle plus Dex group using the Student-Newman-Keuls test. B, Results depicted are from a representative experiment in which the mean Ϯ SEM of three to six separate determinations per treatment group are shown. There was a significant main effect of treatment condition on GR-mediated gene activity using one-way ANOVA [F(2,11) ϭ 31.40; P Ͻ 0.001]. These results were replicated in three independent experiments. *, Significant (P Ͻ 0.05) difference from vehicle plus Dex using the Student-Newman-Keuls test.
inducers, endotoxin and lipopolysaccaride (LPS), or with IL-1␤ have all been shown to decrease GR affinity for ligand, and in the case of endotoxin has also led to resistance to the inhibitory effects of Dex on corticosterone secretion (11) (12) (13) 37) . In contrast, one study has reported that in vitro treatment with IL-1␤ has a stimulating effect on GR function (36) , however the experiments on IL-1 involved cell lines that were transiently transfected with an MMTV-CAT plasmid and chemically shocked before treatment with cytokine. Chemical shock is known to be associated with increased GR function; therefore, such manipulation confounds interpretation of the result (30) .
In contrast to the above studies on GR function and affinity, studies examining the effects of IL-1 or IL-1 inducers on GR expression have yielded more mixed results. In fact, although the majority of the above-mentioned studies demonstrated reduced GR function and/or reduced GR affinity for ligand, in those studies that additionally examined GR expression, some found GR down-regulation (12, 15, 17) and, like the present study, others found GR up-regulation (11, 13, 36) . To further complicate attempts to integrate the available data, a number of studies have described changes in GR expression in the absence of functional data, and both GR down-regulation by endotoxin (14) and LPS (16) and upregulation by LPS (38) have been described. Of note is that patients with ongoing immune activation and GR resistance have been shown to exhibit decreased GR affinity and GR up-regulation (see below). One explanation for these discrepant findings regarding receptor expression is the specific characteristics of the different treatments (IL-1␣ vs. IL-1␤ vs. IL-1 inducers) and of the various cell lines and/or experimental conditions in each study. The regulation of transcription of GR messenger RNA (mRNA), for example, appears to be under the control of several different promoters, the utilization of which is a function of cell and tissue phenotype (Seckl, J., personal communication). Moreover, changes in GR expression (as well as function) occur as a cumulative result of a number of distinct steps, including receptor assembly, phosphorylation, interactions with heat shock proteins, and regulation by transcription factors. Therefore, it is very likely that different cytokines may have tissue-specific effects on GR expression and eventually function. In addition, among the studies showing cytokine-induced GR resistance, those examining cells treated with IL-1 for 24 -48 h or, notably, tissues from patients with chronic inflammatory diseases consistently show GR up-regulation (11, 20, 21, 25, 36, 39) , whereas shorter in vitro or in vivo treatments with IL-1 or IL-1 inducers (4 -6 h) are associated with GR down-regulation (12, 14 -17) . It is noteworthy that the majority of the studies showing receptor down-regulation after short term treatments have also measured cytosolic GR binding; therefore, decreased cytosolic GR binding after short term cytokine treatments may be a function of the kinetics and compartmentalization of the receptor during the acute response to cytokines, as opposed to being a qualitatively different effect. Interestingly in this regard, a study by Verheggen et al. (13) found LPS-and IL-1␤-induced GR up-regulation in the absence of increased GR mRNA, suggesting that increased GR mRNA translation or half-life or alterations in GR compartmentalization were involved.
IL-1␣ alone increased CAT activity by about 25% after 24 h of treatment. The magnitude of this increase is similar to that seen after 1.5 h of treatment with 10 nm Dex, but much smaller than that seen after 24 h of treatment with 10 nm Dex, which induces CAT activity 700-2500% above that with vehicle. IL-1␣-induced increases in CAT activity may represent the results of up-regulated GR. Nevertheless, as these experiments employed media stripped of endogenous steroids, the mechanism underlying the increased CAT activity remains unclear. We suggest that continuous recirculation of GR may occur in the unstimulated condition, thus leading to a baseline activation of CAT activity, which is influenced mostly by the number of GRs. GR trafficking under these conditions may be insensitive to the inhibitory effects of IL-1. On the contrary, GR activation by steroids, such as Dex, even at low doses involves several distinct steps, and one or more of these may be affected by the presence of IL-1. Clearly, this mechanism needs further elaboration.
Mechanisms of the effects of IL-1␣ on GR
IL-1␣ exerts its effects by interacting with specific membrane receptors, followed by activation of second messenger pathways, regulation of protein kinases or phosphatases, and, finally, activation of transcription factors such as nuclear factor-B (40). Fibroblasts contain mRNA for both the type I and the type II IL-1 receptor, but only the type I receptor appears to be biologically active (41) . Although the exact IL-1 signal transduction pathway has not been established for fibroblasts, interactions with G proteins to activate adenylate cyclase as well as stimulation of Ca 2ϩ influx have been suggested (42, 43) . Furthermore, there is evidence that protein phosphorylation (by mitogen-activated, tyrosine, or ␤-casein kinases) also plays a role in fibroblast responses to IL-1 (40, 43, 44) . There is, however, no consensus as to how proximal the kinase cascade is to the IL-1 receptor. Of note, responsiveness of human fibroblasts to IL-1 in vitro occurs when cells are plated on fibronectin, as in our experiments, as opposed to poly-l-lysine (43) . Glucocorticoid hormones, in turn, modulate the effects of cytokines by specifically targeting the induction of transcription factors. For example, activated GR has been shown to either inhibit cytokine-induced synthesis of these transcription factors or to increase the levels and activity of transcription factors inhibitors, such as inhibitory factor B (45, 46). These pathways are believed to be crucial to the immunomodulatory and immunosuppressive effects of glucocorticoid hormones. However, activation of protein kinases and transcription factors by IL-1␣ is probably a relevant mechanism by which these compounds might modify GR function and expression. First, phosphorylation of the GR and/or other nuclear substrates from cAMP-dependent protein kinase may have a relevant role in the regulation of GR function. For example, both adenyl cyclase and protein kinase A activators have been found to influence GR function (47) . Moreover, cell lines containing a defective cAMP-dependent protein kinase give rise to glucocorticoid-resistant variants at a high frequency (48) . Second, protein-protein interaction has been described to occur between GR and nuclear factor-B (49) and between GR and c-Jun, one of the components of activating protein-1 (50, 51) , and reciprocal functional antagonism has been described. Alternatively, cytokines may act on heat shock proteins, one of the constituents of the GR complex. In fact, cytokines, including IL-1␣, have been shown to induce heat shock proteins (52) , and stabilization of GR/90-kDa heat shock protein interaction by sodium molybdate has been associated with inhibition of Dex-induced GR translocation (53) much like that produced by IL-1␣.
Clinical relevance
The experimental evidence suggesting that cytokines decrease GR function is consistent with the well known presence of glucocorticoid resistance in subpopulations of patients with acute or chronic inflammatory diseases, such as sepsis, asthma, ulcerative colitis, acquired immunodeficiency syndrome, rheumatoid arthritis, and allogenic organ transplantation (24) . Specifically, studies performed in peripheral tissues of patients with the above-mentioned diseases, especially those showing resistance to therapeutic effects of glucocorticoids, have demonstrated changes in GR number and function similar to those induced in vivo and in vitro by treatment with cytokines and immune system activators, i.e. reduced effects of glucocorticoids on functional endpoints (19, 23, 37, 54) , reduced GR affinity for the ligands (20, 21, 25) , and GR up-regulation (20, 21, 25, 39) . Interestingly, these GR abnormalities revert to normal after in vitro tissue culture (21) . Moreover, these GR abnormalities recover when patients are treated with very high doses of glucocorticoids, possibly due to the effects of these hormones on glucocorticoid-sensitive immune cells leading to a decrease in ongoing immune activation (22) . Finally, GR resistance seems to be tissue specific, as suggested by the clinical evidence that asthmatic patients who fail to show therapeutic responses to high doses of glucocorticoids nevertheless exhibit features of glucocorticoid excess (Cushingoid features) in other tissues (24) . Therefore, converging evidence suggests that local concentrations of cytokines produced during an inflammatory response may produce an acquired, localized GR resistance. Inhibition of GR translocation, as shown in vitro in the present report, may be a relevant step in this process. It is also of note that the psychiatric disorder, major depression, has also been associated with GR resistance (hypercortisolemia, reduced feedback inhibition on the HPA axis, and decreased sensitivity of peripheral tissues to the effects of glucocorticoids) as well as evidence of inflammation, including increased levels of proinflammatory cytokines and acute phase reactants (55, 56) . Moreover, we have recently demonstrated that the tricyclic antidepressant desipramine increases GR translocation and Dex-induced GRmediated gene transcription (31) , an effect that is virtually the opposite of the effects of IL-1␣ described here. Therefore, it is intriguing to speculate that cytokines produced in the brain or periphery may contribute to the pathogenesis of GR resistance described in patients with major depression, and antidepressants may overcome these receptor alterations.
In summary, our results show that IL-1␣ inhibits Dexinduced GR translocation and Dex-induced GR-mediated gene transcription and induces up-regulation of the cytosolic receptor. This impact on the GR may be an important mechanism by which cytokines produced during an inflammatory response may directly modulate the capacity of glucocorticoids to transmit signals to target tissues and induce GR resistance in relevant cell types, therefore providing an additional pathway by which the immune system can influence the HPA axis and, ultimately, disease expression.
